FDA-Approved Medicines
Michael S. Kinch
Washington University in St Louis, St Louis, MO, USA
Search for more papers by this authorMichael S. Kinch
Washington University in St Louis, St Louis, MO, USA
Search for more papers by this authorAbstract
Although medicines have been needed for the entire span of human existence, the age of pharmaceuticals is a relatively recent era. The benefits accompanying the introduction of new medicines meant to combat age-old maladies have dramatically altered public health and society. Herein, we review the history of drug discovery, demonstrating a constant evolution in both the approaches utilized and the outcomes of technological and scientific advances. These innovations have come with a cost as reflected in the ever-increasing amounts of resources to develop a medicine. Indeed, we see the industry, as currently configured, is faced with unprecedented challenges that could soon threaten its very existence.
References
- 1Kinch, M.S., Kinch, G.A., and Griesenauer, R.H. (2019). Lost medicines: a longer view of the pharmaceutical industry with the potential to reinvigorate discovery. Drug Discov. Today 24 (2): 382–389.
- 2Hanzlik, P.J. (1929). 125th anniversary of the discovery of morphine by sertürner. J. Am. Pharm. Assoc. 18 (4): 375–384.
10.1002/jps.3080180413 Google Scholar
- 3Kinch, M.S. (2016). A Prescription for Change. Chapel Hill, NC: UNC Press.
10.5149/northcarolina/9781469630625.001.0001 Google Scholar
- 4London, J. (2014). Tragedy, transformation, and triumph: comparing the factors and forces that led to the adoption of the 1860 adulteration act in England and the 1906 pure food and drug act in the United States. Food Drug Law J. 69 (2): 315–342, ii–iii.
- 5Ballentine, C. (1981). Taste of raspberries, taste of death: the 1937 elixir sulfanilamide incident. FDA Consumer Magazine 15 (5).
- 6Wax, P.M. (1994). Elixir sulfanilamide-massengill revisited. Vet. Hum. Toxicol. 36 (6): 561–562.
- 7Annas, G.J. and Elias, S. (1999). Thalidomide and the titanic: reconstructing the technology tragedies of the twentieth century. Am. J. Public Health 89 (1): 98–101.
- 8Bren, L. (2001). Frances oldham kelsey: FDA medical reviewer leaves her mark on history. FDA Consum. 35 (2): 24–29.
- 9Goodrich, W.W. (1963). FDA's regulation under the Kefauver–Harris drug amendments of 1962. Food Drug Cosm. Law J. 18: 561.
- 10Mossinghoff, G.J. (1999). Overview of the Hatch–Waxman act and its impact on the drug development process. Food Drug Law J. 54 (2): 187–194.
- 11Berndt, E.R., Gottschalk, A.H., Philipson, T.J., and Strobeck, M.W. (2005). Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Nat. Rev. Drug Discov. 4 (7): 545–554.
- 12Patridge, E., Gareiss, P., Kinch, M.S., and Hoyer, D. (2015). An analysis of FDA-approved drugs: natural products and their derivatives. Drug Discov. Today 21: 204–207.
- 13Adams, D.A., Jajosky, R.A., Ajani, U., Kriseman, J., Sharp, P., Onwen, D.H., Schley, A.W. et al. (2014). Summary of notifiable diseases – United States, 2012. MMWR Morb. Mortal. Wkly. Rep. 61 (53): 1–121.
- 14Kinch, M.S., Patridge, E., Plummer, M., and Hoyer, D. (2014). An analysis of FDA-approved drugs for infectious disease: antibacterial agents. Drug Discov. Today 19 (9): 1283–1287.
- 15 Department of Health and Human Services (2019). About heart disease & stroke. https://millionhearts.hhs.gov (accessed 1 April 2019).
- 16Altman, L.K. (2010). Dr. James black, pharmacologist who discovered beta blockers, dies at 85 New York times. https://www.nytimes.com/2010/03/23/health/23black.html (accessed 22 March 2010).
- 17Goodman, L.S., Wintrobe, M.M., Dameshek, W., Goodman, M.J., Gilman, A., and McLennan, M.T. (1984). Landmark article Sept. 21, 1946: nitrogen mustard therapy. Use of methyl-bis(beta-chloroethyl)amine hydrochloride and tris(beta-chloroethyl)amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 251 (17): 2255–2261.
- 18Infield, G.B. (1974). Disaster at Bari. London: Hale.
- 19Engelking, C. (2016). Germ of an idea: William Coley's cancer-killing toxins. Discover Magazine (21 April 2016).
- 20Kinch, M.S. (2019). End of the Beginning: Cancer, Immunity and the Future of Cure. New York: Pegasus Books.
- 21Kienle, G.S. (2012). Fever in cancer treatment: Coley's therapy and epidemiologic observations. Glob. Adv. Health Med. 1 (1): 92–100.
- 22Tontonoz, M. (2019). Beyond magic bullets: Helen Coley nauts and the battle for immunotherapy. Cancer Research Institute. Beyond Magic Bullets: Helen Coley Nauts and the Battle for Immunotherapy (accessed 1 April 2019).
- 23Tsaioun, K. and Jacewicz, M. (2009). De-risking drug discovery with ADDME – avoiding drug development mistakes early. Altern. Lab. Anim. 37 (Suppl 1): 47–55.
- 24Tollenaere, J.P. (1996). The role of structure-based ligand design and molecular modelling in drug discovery. Pharm. World Sci. 18 (2): 56–62.
- 25Williams, A. and Friedland, G. (1997). Adherence, compliance, and HAART. AIDS Clin. Care 9 (7): 51–54.
- 26Munos, B. (2009). Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8 (12): 959–968.
- 27Evens, R.P. and Kaitin, K.I. (2014). The biotechnology innovation machine: a source of intelligent biopharmaceuticals for the pharma industry. Clin. Pharmacol. Ther. 95 (5): 528–532.
- 28 Pharmaceutical Research and Manufacturers of America (2015). 2015 Biopharmaceutical Research Industry Profile. Washington, DC: Pharmaceutical Research and Manufacturers of America. http://www.phrma.org/profiles-reports.
- 29Scannell, J.W., Blanckley, A., Boldon, H., and Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11 (3): 191–200.
- 30 Tufts Center for the Study of Drug Development (2014). Cost to develop and win marketing approval for a new drug is $2.6 billion. https://csdd.tufts.edu/csddnews/2018/3/9/march-2016-tufts-csdd-rd-cost-study (9 March 2014) (accessed 1 April 2019).
- 31Prakash, S. and Valentine, V. (2019). Timeline: the rise and fall of vioxx. https://www.npr.org/2007/11/10/5470430/timeline-the-rise-and-fall-of-vioxx (accessed 1 April 2019).
- 32Alberts, A.W. (1988). Discovery, biochemistry and biology of lovastatin. Am. J. Cardiol. 62 (15): J10–J15.
- 33Sobota, J.T. and Copmann, T.L. (1990). Orphan drug act. Science 249: 346–347.
- 34Griesenauer, R.H. and Kinch, M.S. (2017). 2016 in review: FDA approvals of new molecular entities. Drug Discov. Today 22 (11): 1593–1597.
- 35Kinch, M.S. and Moore, R. (2016). Innovator organizations in new drug development: assessing the sustainability of the biopharmaceutical industry. Cell Chem. Biol. 23 (6): 644–653.
- 36Loftus, P., Falconi, M., and Plumridge, H. (2014). In drug mergers, there's one sure bet: the layoffs. Wall Street Journal (29 April 2014).
- 37Buvailo, A. (2018). Pharma R&D outsourcing is on the rise. BiopharmaTrend.com. https://www.biopharmatrend.com/post/30-pharma-rd-outsourcing-is-on-the-rise/ (13 August 2018) (accessed 1 April 2019).